Clinical Trial: NCT04684147
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Juventas Cell Therapy Ltd. |
| Information Provided By: | Juventas Cell Therapy Ltd. |
| Last Update Posted: | 2025-08-08 |
Study Overview
Brief Summary
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.
Official Title
Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions
Relapsed or Refractory Acute Lymphoblastic Leukemia
Intervention / Treatment
- Biological: single dose of CNCT19
Other Study ID Numbers
- HY001201
Start Date (Actual)
2020-12-24
Primary Completion Date (Actual)
2022-09-22
Study Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
100
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Juventas Cell Therapy Ltd. |
| Information Provided By: | Juventas Cell Therapy Ltd. |
| Last Update Posted: | 2025-08-08 |
Study Overview
Brief Summary
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.
Official Title
Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions
Relapsed or Refractory Acute Lymphoblastic Leukemia
Intervention / Treatment
- Biological: single dose of CNCT19
Other Study ID Numbers
- HY001201
Start Date (Actual)
2020-12-24
Primary Completion Date (Actual)
2022-09-22
Study Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
100
Study Type
Interventional
Phase
Phase 2